What is Protara Therapeutics Inc (TARA) stock price today?

Protara Therapeutics Inc (TARA) currently trades at $5.33 per share. The stock has a market capitalization of $273.67M and a P/E ratio of —x.

Is TARA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Protara Therapeutics Inc has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 5.00.

Is Protara Therapeutics Inc financially healthy?

Protara Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 5.00 places it in the safe zone.

TARA

Protara Therapeutics Inc

NASDAQ: TARA · HEALTHCARE · BIOTECHNOLOGY

$5.33

+3.09% today

Updated 2026-04-30

Market cap

$273.67M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.34

Dividend yield

—

52W range

$3 – $8

Volume

1.0M

Market cap

$273.67M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.34

Dividend yield

—

52W range

$3 – $8

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

5.0

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$25.71

+382.36%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 5.00 — safe zone

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-16.97M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-65.95M	$-40.42M	$-44.60M	$-57.44M	$-17.31M
EPS	—	—	—	—	$-1.34
Free cash flow	$-26.58M	$-37.60M	$-35.87M	$-56.46M	$-16.97M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TARA	$273.67M	29	4.3	3.0	5.0	8.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Protara Therapeutics Inc trades at $5.33. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 5.00, it sits in the safe zone.

Frequently asked questions

What is Protara Therapeutics Inc's stock price?

Protara Therapeutics Inc (TARA) trades at $5.33.

Is Protara Therapeutics Inc overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Protara Therapeutics Inc (TARA)?

The analyst target price is $25.71, representing +382.4% upside from the current price of $5.33.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

5.00 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.protaratx.com

Quick metrics

P/S ratio—

ROE-31.60%

Beta1.50

50D MA$5.53

200D MA$4.99

Shares out0.05B

Float0.05B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TARA vs LLY →TARA vs JNJ →TARA vs ABBV →Stock screener →